SuperworthVivos Therapeutics shares outstanding VVOS
Diluted shares outstanding, averaged over each quarter, from 2020.
- Latest quarter, to Jun 30, 2026
- 17.7M
- On a year earlier
- +94.6%
- more shares
Vivos Therapeutics had 17.7M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 94.6% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 12.4M | +72% |
| FY2024 | 7.2M | +409% |
| FY2023 | 1.4M | +25% |
| FY2022 | 1.1M | +23% |
| FY2021 | 920.5K | +67% |
| FY2020 | 551.9K | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 17.7M | +95% | |
| Q1 FY26 | 14.6M | +70% | |
| Q4 FY25 | 12.4M | +72% | |
| Q3 FY25 | 11M | +66% | |
| Q2 FY25 | 9.1M | +181% | |
| Q1 FY25 | 8.6M | +272% | |
| Q4 FY24 | 7.2M | +409% | |
| Q3 FY24 | 6.6M | +453% | |
| Q2 FY24 | 3.2M | +170% | |
| Q1 FY24 | 2.3M | +133% | |
| Q4 FY23 | 1.4M | +25% | |
| Q3 FY23 | 1.2M | +41% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Vivos Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.